Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study

Table 3

Comparison of CBC findings in chronic HCV patients and healthy controls.

	Before	After	Control	P value
Hb (g/dl)				0.223
Mean ±SD	14.11±1.25	13.50±1.35	13.68±0.42
Median (range)	14.3(11.8-17.2)	13.55(10.8-16.5)	13.9(11.2-15.6)
Platelet count (10^9/l)				0.516
Mean ±SD	223.350±72.390	219.770±54.770	222.000±32.520
Median (range)	201(133-479)	215(122-323)	218(172-271)
WBC (10^9/l)				0.311
Mean ±SD	6.722±2.754	6,315±1,872	6.920±1.414
Median (range)	6.010(3.000-14.600)	5.850(3.600-10.800)	7.200(4.000-8.800)
ANC (10^9/l)				0.695
Mean ±SD	3,766±2.425	3,378±1.273	3.964±1.273
Median (range)	3,091(1.200-11.826)	3,470(0.966-5.785)	4,320(2400-559)
Neutrophil				0.789
Mean ±SD	52.69±13.03	52.96±12.28	56.8±12.02
Median (range)	53.5 (26-81)	55(23-73)	60(43-65)
ALC(10^9/l)				0.614
Mean ±SD	2.286±677	2.403±960	2.530±1.230
Median (range)	2.258 (1.050-4.214)	2.297(0.980-5.724)	2.448(1.440-3.344)
Lymphocyte				0.817
Mean ±SD	37.31±11.94	38.35±9.70	37.4±12.02
Median (range)	36(11-65)	37.5(20-67)	36(26-53)
AMC(10^9/l)				0.003
Mean ±SD	497±0.275	286±145	313± 14
Median (range)	400 (132-1287)	278(41-651)	264(160-602)
monocyte				0.00001
Mean ±SD	7.58±2.39	4.58±1.65	4.4±0.71
Median (range)	7.5(3-11)	4.5(1-8)	4(3-7)
AEC (10^9/l)				0.024
Mean ±SD	20.19±15.65	12.72±8.32	12.96±1.41
Median (range)	17.4(0-68.4)	12.4(0-27.6)	8(6-26.4)
Eosinophil				0.076
Mean ±SD	3.19±2.76	2.039±1.34	1.8±0.71
Median (range)	2(1-12)	2(1-5)	2(1-3)
NMR	8.27±4.5	14.82±11.17	13.86±0.47	0.022
	7.01(3.5-20)	12(5.2-60)	14.33(9.29-18.67)
LMR	5.75±3.17	10.58±7.19	9.97±6.13	0.008
	5.3(1.6-16.25)	8.15(3.3-37)	9(3.71-17.67)

Significant; AEC: absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; LMR: lymphocyte to monocyte ratio. NMR: neutrophil to monocyte ratio.